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Table 1 Comparative results of three glanders serological tests on 182
equine sera from Bahrain expressed as positive percentage.
ID SAMPLE
NUMBER
CCPRO
CFT %
CVRL
cELISA%
FLI WB%
Horse Panel A 53 96.2 (51/53) 98.1 (52/53) 98.1 (52/53)
Horse Panel B 43 90.7 (39/43) 95.3 (41/43) 90.7 (39/43)
Horse Panel C 86 34.9 (30/86) 0 (0/86) 0 (0/86)
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Equine infectious anemia (EIA) is a disease of high economic
impact on the equine industry worldwide. Since horses are
frequent travelers, EIA falls under strict regulatory control pro-
grams in many countries. In Argentina the national animal health
authority (SENASA) states that all horses imported, moving
within the country, or congregating at public assemblies must
have a negative EIA report conducted within the previous 2
months. The agent causing EIA is a RNAvirus from the Retroviridae
family and its major capsid protein named p26 is the most
immunogenic protein in the viral particle. Thus, the detection of
speciﬁc antibodies directed to p26 is the aim ofmost diagnosis tests
available in the world. The agar gel immunodifusion (AGID) is the
ofﬁcially accepted method to certify the diagnosis of EIA in
Argentina. Since 2009 IncuINTAwas working on the scaling up and
production of the KIT AIE IDGA RP26, an Argentinean AGID test
entirely developed in the laboratory containing a recombinant p26
protein to detect EIA antibodies in horses’ serum. Until 2015
IncuINTA produced two pilot batches and six commercial batches
(one per year) containing from 24000 determinations in 2011 to
39600 determinations in 2015. Since the product was launched in
2011, the sales were increased 109%. Up to date we have placed on
the market 170640 determinations. As expected, the number of
laboratories buying the KIT AIE IDGA RP26 was also increasing
through time being 26 in 2011 and 36 in 2015. This number of
clients represents 17% of the 207 laboratories authorized by SENASA
to diagnose EIA in Argentina. These laboratories are located mostly
in Buenos Aires, Santa Fe, Entre Ríos, Formosa, La Pampa, Rio Negro,
Cordoba, Corrientes, Salta and Tucuman provinces. Until 2009 there
was no Argentinean EIA test available in our market being the
imported ones very expensive. IncuINTA,which is a R&D laboratory,
could scale up, produce and sell the KIT AIE IDGA RP26 during six
consecutive years. After this success, IncuINTA perspective is to
increase the number of batches each year to be able to attend the
demand of most diagnosis laboratories in the country.
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In recent years, an increase in the number of cases of equine
neurological disease caused by equine herpes virus 1 (EHV1)
neuropathogenic variants, has been observed in numerous
countries. The purpose of this study was to detect the presence of
the viral genome of EHV1 and equine herpes virus 4 (EHV4) in
bronchopulmonary lymph nodes of 47 horses, from various lo-
cations of Uruguay, obtained in a slaughterhouse. The genes
encoding the glycoprotein H (gH) of EHV1 and B (gB) of EHV4were ampliﬁed by a semi-nested PCR. Of the total samples
analyzed, 27% and 6% of lymph nodes contained the gene for gH
and gB, respectively. To determine whether the genomes of EHV1
possess the mutation associated with neuropathogenesis (G2254
/ D752), the gene for the viral DNA polymerase was ampliﬁed and
sequenced. One of the ﬁve genomes sequenced presented the
mutation. The results conﬁrm the presence of EHV1 in our
country. Furthermore, there is evidence for the ﬁrst-time detec-
tion of EHV4 and the neuropathogenic variant (G2254 / D752) of
EHV1 in Uruguay. This ﬁnding provides new insights into the
epidemiological situation of EHV-1 and EHV-4 in our country.
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Glanders is a zoonotic disease caused by Burkholderia mallei. It is
an OIE (Ofﬁce International des Epizooties) listed disease which
may affect a variety of animal species but mainly equids. For in-
ternational trade of horses, donkeys and mules, the complement
ﬁxation test (CFT) is the OIE acknowledgedmain test (OIEManual,
2016, in press). However, in recent years researches from different
countries have established new serological tests to overcome
cross reactions (Neubauer et al., 2005; Naureen et al., 2007;
Sprague et al., 2009 & Elschner et al., 2011) which sometimes
hamper international trade. Additionally, serological results from
donkeys andmules as well as from older equine samples are often
difﬁcult to interpret due to anti complementary reactions (Wer-
nery et al., 2012). An outbreak of glanders in Bahrain in 2010/11
(Scholz et al., 2014) provided the opportunity to compare
different serological tests on 182 equine sera. The 182 horses
tested included 53 horses with clinical glanders signs (Panel A),
43 horses which had direct contact with glanderous horses with
no glanders clinical signs (Panel B) and 86 horses with no clinical
signs kept in the outbreak area (Panel C). The results of the
comparison tests are presented in Table 1.References
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EIA is a retroviral disease affecting all equidae and its diagnosis is
principally based on the use of serological methods represented
by agar gel immunodiffusion test (AGIDT), ELISA and the
immunoblot that are used on the basis of the intended purpose.
OIE proposes both AGIDT and ELISA as suitable for the demon-
stration of individual or population freedom from infection.
Important characteristic for a serological method to be used asscreening test in a control programme is its sensitivity that as-
sures the detection of the highest possible number of cases.
Relative to this are different studies reporting on the higher
sensitivity of the ELISA compared to the AGIDT (1, 2). As Italy,
like in many other countries, has a regulatory control program
for EIA, the National Reference Centre for EIA (NRCEIA) con-
ducted a study in which the diagnostic performance of all ELISA
serological kits available in the country, as candidate/s for a
screening test, was evaluated. Ten ofﬁcial laboratories partici-
pated in the study where each examined a sample panel con-
taining negative and positive sera with different levels of
positivity, using four commercial and 2 in-house kits. The same
kits were also assessed for their precocity by the NRCEIA using a
panel of sera from vaccinated animals at different days post-
vaccination. All the serum samples used in this study were also
tested in AGIDT. The parameters evaluated were: diagnostic
sensitivity (DSe) and speciﬁcity (DSp), Cohen K, weighted Cohen
K, coefﬁcient of variation (CV), accordance and concordance. The
results obtained were the following; Dse and DSP for all kits
were 100% deﬁning, all tests as accurate. K multiple was equal to
0.76 while the value of K for all laboratories, compared with each
other was 0.72. The K values indicate a degree of concordance
almost perfect according to the classiﬁcation of Landis et. al. (3).
The CV values obtained for all sera were less than 20%, and for
this repeatability and the reproducibility for the kits evaluated
was satisfactory. Moreover, accordance and concordance were
close to 100% in more than half of the sera. Analysis of these
parameters show that all kits employed have a high diagnostic
performance and also a higher sensitivity than AGID in terms of
analytical sensitivity and precocity. Even if a complete evalua-
tion, according to the OIE standards, is required, all kits resulted
suitable candidates as screening tools capable of increasing the
efﬁcacy of EIA control programmes.References
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